It has been shown that MDM2 displays an elevated expression in various human cancers, such as osteosarcoma, neuroblastoma, lung cancer, colon cancer, breast cancer, and liver cancer, where it enhances p53 degradation, leading to poor survival and prognosis of patients (Table 1) [78,79,80]. This evidence concerns the gene TP53 and cancer.